Research Topics | Kathryn E WilliamsSummaryAffiliation: Pfizer Global Research and Development Country: USA Publications
| Collaborators
|
Detail Information
Publications
A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessationHélène M Faessel
Clinical Pharmacology, Primary Care Unit, Pfizer Inc, New London, Connecticut 06320, USA
Clin Pharmacokinet 49:799-816. 2010..In all, the predictable pharmacokinetic properties and straightforward dispositional profile of varenicline simplify its use in clinical practice...
A double-blind study evaluating the long-term safety of varenicline for smoking cessationKathryn E Williams
Pfizer Global Research and Development, Groton, CT 06340, USA
Curr Med Res Opin 23:793-801. 2007..We assessed the safety of long-term varenicline administration for smoking cessation...- Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognitionHans Rollema
Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
Biochem Pharmacol 78:813-24. 2009.... - Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessationHans Rollema
Department of Neuroscience Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
Trends Pharmacol Sci 28:316-25. 2007.... - Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trialDavid Gonzales
Smoking Cessation Center, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
JAMA 296:47-55. 2006..TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00141206... - Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trialDouglas E Jorenby
University of Wisconsin School of Medicine and Public Health, Center for Tobacco Research and Intervention, Madison, Wis 53711, USA
JAMA 296:56-63. 2006..Varenicline, a partial agonist at the alpha4beta2 nicotinic acetylcholine receptor, has the potential to aid smoking cessation by relieving nicotine withdrawal symptoms and reducing the rewarding properties of nicotine... - Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trialSerena Tonstad
Department of Preventive Cardiology, Ulleval University Hospital, and University of Oslo, Oslo, Norway
JAMA 296:64-71. 2006..The majority of cigarette smokers who achieve abstinence relapse within the first year and require many attempts before achieving permanent abstinence. Evidence to support pharmacological treatment for relapse prevention is insufficient... - A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokersShih Tzu Tsai
Department of Community Medicine, Buddhist Tzu Chi General Hospital and Tzu Chi University College of Medicine, Hualien, Taiwan
Clin Ther 29:1027-39. 2007..Rates of smoking in East Asian men range from >35% to >60%, and are increasing in women and the young... - The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trialRaymond Niaura
Brown University, Providence, RI, USA
Curr Med Res Opin 24:1931-41. 2008..To determine whether self-regulated flexible dosing with varenicline tartrate is safe and effective for smoking cessation...